Generex Biotechnology Corporation (Nasdaq:GNBT) (www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that it has been awarded two new patents in Japan and Ukraine.
The Commissioner of the Japan Patent Office granted the Company a patent titled "Mixed Micellar Pharmaceutical Delivery System and Method of Preparation." Patent number 449282 is registered in the Japan Patent Office.
The Ukranian State Register of patents and inventions granted the Company patent number 90346 titled "Orally absorbed pharmaceutical formulation and method of administration."
These new patents increase the number of issued patents related to the Company's buccal drug delivery platform technologies to 160. A total of 103 patent applications are pending.
"Each new patent issuance establishes the inventiveness of the Company's buccal drug delivery platform technologies," stated Rose C. Perri, the Company's Chief Operating Officer. "We are pleased that we continue to receive patents from key markets within which our delivery system can be commercialized with a pipeline of viable applications that will open up other marketplaces for the Company."
Obesity crisis in the U.S. expected to worsen by 2050